The Precision Medicine World Conference 2018 Silicon Valley (PMWC 2018 SV) kicked off on Sunday evening January 21 with a special awards ceremony at Genentech Hall on the Mission Bay campus of the University of California-San Francisco (UCSF). UCSF hosted the ceremony and Keith Yamamoto, PhD, Vice Chancellor for Research, Executive Vice Dean of the School of Medicine, and Professor of Cellular and Molecular Pharmacology at UCSF, MC’d the event. The PMWC 2018 Luminary Award was presented to Emmanuelle Charpentier (photo receiving award from Dr. Yamamoto), PhD, for spearheading the development of the groundbreaking CRISPR-Cas9 genome editing technology. With this award, the PMWC recognizes recent contributions of preeminent figures who have accelerated personalized medicine into the clinical marketplace. The PMWC 2018 Pioneer Awards were presented to Alan Ashworth, PhD, for co-discovering the BRCA2 gene mutation and making discoveries leading to PARP inhibition in breast and other cancers; to Professor Sir John Bell, of Oxford University, for leading genetic and genomic research initiatives that enable precision medicine in the UK and globally; and to Ronald Levy, MD, for developing the first FDA-approved antibody for the treatment of cancer (rituximab). With its Pioneer Awards, the PMWC recognizes rare individuals who have presaged the advent of personalized medicine when less evolved technology and encouragement from peers existed, but still made major advances in the field. Previous PMWC award recipients include Jennifer Douda, Lee Hood, George Church, and Francis Collins. The general PMWC 2018 SV meeting officially opens on Monday, January 22 and runs through Wednesday, January 24 (http://www.pmwcintl.com/2018sv-info/). It will be held at the Computer History Museum in Mountain View.
Login Or Register To Read Full Story